A prospective, 26-week, open-label, multi-center, single-arm pilot study to evaluate the safety and tolerability of rivastigmine capsule with add on memantine HCl in patients with probable Alzheimer's disease (MMSE 10-20)
Phase of Trial: Phase IV
Latest Information Update: 18 Jan 2010
At a glance
- Drugs Memantine; Rivastigmine
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Novartis
- 20 Nov 2007 Status changed from in progress to completed.
- 16 Oct 2006 New trial record.